- Home
- LDWY vs GTBP Comparison
LDWY vs GTBP Comparison
Compare LDWY & GTBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDWY
- GTBP
- Stock Information
- Founded
- LDWY 1990
- GTBP 1965
- Country
- LDWY United States
- GTBP United States
- Employees
- LDWY N/A
- GTBP N/A
- Industry
- LDWY Advertising
- GTBP Biotechnology: Pharmaceutical Preparations
- Sector
- LDWY Consumer Discretionary
- GTBP Health Care
- Exchange
- LDWY Nasdaq
- GTBP Nasdaq
- Market Cap
- LDWY 6.9M
- GTBP 6.6M
- IPO Year
- LDWY 1991
- GTBP N/A
- Fundamental
- Price
- LDWY $3.69
- GTBP $2.91
- Analyst Decision
- LDWY
- GTBP
- Analyst Count
- LDWY 0
- GTBP 0
- Target Price
- LDWY N/A
- GTBP N/A
- AVG Volume (30 Days)
- LDWY 5.1K
- GTBP 28.9K
- Earning Date
- LDWY 11-29-2024
- GTBP 11-14-2024
- Dividend Yield
- LDWY N/A
- GTBP N/A
- EPS Growth
- LDWY N/A
- GTBP N/A
- EPS
- LDWY N/A
- GTBP N/A
- Revenue
- LDWY $24,813,000.00
- GTBP N/A
- Revenue This Year
- LDWY N/A
- GTBP N/A
- Revenue Next Year
- LDWY N/A
- GTBP N/A
- P/E Ratio
- LDWY N/A
- GTBP N/A
- Revenue Growth
- LDWY N/A
- GTBP N/A
- 52 Week Low
- LDWY $3.02
- GTBP $1.92
- 52 Week High
- LDWY $6.88
- GTBP $10.66
- Technical
- Relative Strength Index (RSI)
- LDWY 54.80
- GTBP 55.53
- Support Level
- LDWY $3.31
- GTBP $2.94
- Resistance Level
- LDWY $3.99
- GTBP $3.54
- Average True Range (ATR)
- LDWY 0.21
- GTBP 0.27
- MACD
- LDWY 0.02
- GTBP -0.02
- Stochastic Oscillator
- LDWY 44.87
- GTBP 23.05
About LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in two Industry Specialty Ag, consisting of the Bloomia business, and Non-bank Lending, consisting of the Lending Business.
About GTBP GT Biopharma Inc.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.